New cocktail aims to tackle tough myeloma cases

NCT ID NCT01242267

Completed Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of thalidomide, bortezomib, and high-dose melphalan followed by a stem cell transplant in 29 patients with advanced multiple myeloma who had already failed one round of treatment. The goal was to find the safest dose of thalidomide and see how well the combo worked. Researchers measured side effects, response rates, and how long patients stayed in remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: thalidomide, bortezomib, melphalan, and stem cell transplant
What this could lead to: If successful, this combination could offer a new treatment option for patients with advanced multiple myeloma who have not responded to previous therapy.
What could go wrong: This is an early-phase trial with only 29 participants, so results may not apply broadly. The combination of drugs can cause significant side effects, and the study focuses on finding the safest dose rather than proving effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell leukemia plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.